Rehospitalization, Emergency Visits After Paxlovid Treatment Are Rare

Hospitalizations and emergency department visits for rebounding COVID-19 symptoms are rare after treatment with the antiviral therapy nirmatrelvir-ritonavir, according to a CDC analysis of electronic medical records from a large health care system.

In late December 2021, the US Food and Drug Administration issued an Emergency Use Authorization for nirmatrelvir-ritonavir (Paxlovid) to treat individuals with COVID-19 at increased risk of severe outcomes including hospitalization and death. Case reports of rebounding COVID-19 symptoms or positive SARS-CoV-2 test results between 2 and 8 days after treatment with the antiviral therapy prompted the CDC to issue a Health Advisory on May 24.

Less than 1% of 5287 patients who received nirmatrelvir-ritonavir for COVID-19 required hospitalization or emergency department care for symptoms 5 to 15 days after treatment, according to the CDC report. Six hospitalizations—all among people with comorbidities or advanced age—and 39 emergency department encounters for apparent COVID-19 symptoms occurred. Two of the hospitalized patients died.

“When administered as an early-stage treatment, Paxlovid might prevent COVID-19–related hospitalization among persons with mild to moderate COVID-19 who are at risk for progression to severe disease,” the report’s authors wrote.

https://jamanetwork.com/journals/jama/fullarticle/2794553?guestAccessKey=4cbc92b4-1611-469d-a87f-88b44c24398c&utm_source=fbpage&utm_medium=social_jama&utm_term=7314646722&utm_campaign=article_alert&linkId=174824596&fbclid=IwAR2waRobmZa26Cr-STZ_hvixBsGNNBqXzZAqhtliBNQY0abrHs3A8ghBSi4

Créditos: Comité científico Covid